In our most recent Mobility Outlook Survey for 2023, 30% of companies are expecting an increase in the use of Developmental, Graduate, and Intern policies.
Recent Posts
AIRINC facilitated another Pharma, Biotech, and medical device round table session with strategic leaders from around the globe to share industry insights and discuss their program challenges and focuses for 2023.
In August 2019, my partner received a job offer he couldn’t pass up, so I asked to relocate from Boston to New York City. Fortunately, AIRINC accepted my request to become a fully remote worker.
2020 was the most challenging year for Global Mobility. However, it gave mobility teams the time to reflect and demonstrate their value and global perception to their overall organizations. Global Mobility’s goals remain steadfast in a pre-, during-, and post-COVID-19 world: to help attract and retain key global talent. The results from Pharmaceutical companies in the Mobility Outlook Survey indicate this mission is still in the forefront for the coming year with increased focus on how mobility can best serve their customers, business functions, and assignees.
Takeaways from the 2021 Mobility Outlook Survey: Financial Services 2020 was a very challenging year for Global Mobility. However, it gave mobility teams the time to reflect and demonstrate their value and global perception to their overall organizations. Global Mobility’s goals remain steadfast in a pre-, during-, and post-COVID-19 world: to help attract and retain key global talent.
Recent approvals for COVID-19 vaccines have led to questions about how or if individuals on international assignments will receive vaccination support from their employers.
The world’s most anticipated vaccine is coming! As countries prepare their vaccination plans, where do expatriates fit in? Participate in this short poll to learn how other companies are supporting employees who wish to be vaccinated while on international assignment.
As the world continues to grapple with COVID-19, companies are taking this time to understand and learn from this once in a lifetime experience. The Pharma industry has taken this period to focus on the mobility program and strategy. We found 3 key highlights from our recent COVID-19 benchmark.
